Filed: Sep. 30, 2019
Latest Update: Sep. 30, 2019
Summary: ORDER JUAN R. S NCHEZ , Chief District Judge . AND NOW, this 30th day of September, 2019, upon consideration of Defendant GlaxoSmithKline LLC's (GSK) "Motion to Exclude the Expert Testimony of Philip Russ, Drs. David Kessler, Matthew Perri, Stephen Schondelmeyer, and Rena Conti," the briefing thereon, and the parties' presentations at the March 12, 2019 oral argument on the Motion, and for the reasons set forth in the accompanying Memorandum, it is ORDERED the Motion (Document 202) is GRAN
Summary: ORDER JUAN R. S NCHEZ , Chief District Judge . AND NOW, this 30th day of September, 2019, upon consideration of Defendant GlaxoSmithKline LLC's (GSK) "Motion to Exclude the Expert Testimony of Philip Russ, Drs. David Kessler, Matthew Perri, Stephen Schondelmeyer, and Rena Conti," the briefing thereon, and the parties' presentations at the March 12, 2019 oral argument on the Motion, and for the reasons set forth in the accompanying Memorandum, it is ORDERED the Motion (Document 202) is GRANT..
More
ORDER
JUAN R. SÁNCHEZ, Chief District Judge.
AND NOW, this 30th day of September, 2019, upon consideration of Defendant GlaxoSmithKline LLC's (GSK) "Motion to Exclude the Expert Testimony of Philip Russ, Drs. David Kessler, Matthew Perri, Stephen Schondelmeyer, and Rena Conti," the briefing thereon, and the parties' presentations at the March 12, 2019 oral argument on the Motion, and for the reasons set forth in the accompanying Memorandum, it is ORDERED the Motion (Document 202) is GRANTED in part and DENIED in part as follows:
1. The Motion is GRANTED insofar as Dr. David Kessler shall be prohibited from defining "materiality" or referring to certain cGMP violations as having a "material impact";
2. The Motion is GRANTED insofar as Dr. Stephen Schondelmeyer shall be excluded from testifying at trial; and
3. The balance of the Motion is DENIED.
It is further ORDERED Plaintiffs' "Motion for Leave to Submit Two September 3, 2019 Decisions in National Prescription Opiate Litigation as Supplemental Authority" (Document 291) is DENIED.1
